claim: moderna receives confirmation of eligibility for submission of marketing authorization application to the european medicines agency for mrna vaccine against covid-19
evidence_1: modernas investigational zika vaccine (mrna-1893), currently in a phase 1 study, was granted fda fast track designation in august 2019.", "confirmation of eligibility was given in response to the submission of a letter of intent enabling moderna to evaluate the opportunity for submitting a marketing authorization application (maa) for mrna-1273 with the ema.")